Peter Staple - Depomed Independent Chairman of the Board
Chairman
Mr. Peter D. Staple is an Independent Director of the Depomed Inc. He has served as a director of the Company since November 2003. Since March 2008, Mr. Staple has served as President and Chief Executive Officer and a director of Corium International, Inc., a publiclyheld biopharmaceutical company focused on transdermal delivery systems and related technologies to address unmet medical needs. From 2002 to March 2008 he served as director, and from 2002 to November 2007 as Chief Executive Officer, of BioSeek, Inc., a privatelyheld drug discovery company. From 1994 to 2002, Mr. Staple was a member of the senior executive team at ALZA Corporationrationration, where he was most recently Executive Vice President, Chief Administrative Officer and General Counsel. Prior to joining ALZA, Mr. Staple held the position of Vice President, Associate General Counsel for Chiron Corporationrationration, a biopharmaceutical company. Mr. Staple previously served as Vice President and Associate General Counsel for Cetus Corporationrationration, a biotechnology company. The Board considered Mr. Staple experience and expertise within the following areas relevant to the Company and its business in concluding that he should serve on the Board Corporationrationrate Management Corporationrationrate Governance Strategic Transactions Corporationrationrate Finance Intellectual Property and Board and Board committee experience since 2017.
| Age | 65 |
| Tenure | 7 years |
| Phone | 224 419-7106 |
| Web | www.assertiotx.com |
Depomed Management Efficiency
The company has return on total asset (ROA) of (0.3054) % which means that it has lost $0.3054 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.602) %, meaning that it created substantial loss on money invested by shareholders. Depomed's management efficiency ratios could be used to measure how well Depomed manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 632.15 M in liabilities with Debt to Equity (D/E) ratio of 306.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Depomed has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Depomed until it has trouble settling it off, either with new capital or with free cash flow. So, Depomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Depomed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Depomed to invest in growth at high rates of return. When we think about Depomed's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Richard Warzala | Allient | 71 | |
| Youpan Liang | Yuexiu Transport Infrastructure | 58 | |
| Charles Shaver | US Silica Holdings | 62 | |
| Chunxiu Zhu | Yuexiu Transport Infrastructure | 52 | |
| Martin Heyningen | KVH Industries | 58 | |
| Howard Lance | Summit Materials | 65 | |
| Yongjie Liu | Yuexiu Transport Infrastructure | 57 | |
| Takao Endo | Renesas Electronics | 61 | |
Management Performance
| Return On Equity | -1.6 | |||
| Return On Asset | -0.31 |
Depomed Leadership Team
Elected by the shareholders, the Depomed's board of directors comprises two types of representatives: Depomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Depomed. The board's role is to monitor Depomed's management team and ensure that shareholders' interests are well served. Depomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Depomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vicente Anido, Independent Director | ||
| Arthur Higgins, President CEO, Director | ||
| Phillip Donenberg, CFO, Senior Vice President | ||
| Samuel Saks, Independent Director | ||
| James Schoeneck, CEO and President and Director | ||
| Robert Savage, Independent Director | ||
| David Zenoff, Independent Director | ||
| Louis Lavigne, Independent Director | ||
| Peter Staple, Independent Chairman of the Board | ||
| James Tyree, Independent Director | ||
| Santosh Vetticaden, Senior Vice President Chief Medical and Scientific Officer | ||
| Sharon Larkin, Senior Vice President - Human Resources and Administration. | ||
| August Moretti, CFO, Senior Vice President | ||
| Stanley Bukofzer, Senior Vice President and Chief Medical Officer | ||
| Richard Shively, Senior Vice President Chief Commercial Officer | ||
| Thadd Vargas, Sr. VP of Bus. Devel. | ||
| Stan Bukofzer, Senior Vice President Chief Medical and Scientific Officer | ||
| Matthew Gosling, Sr. VP and General Counsel | ||
| Gavin Molinelli, Independent Director | ||
| Christopher Keenan, VP, Investor Relations and Corporate Communications | ||
| Karen Dawes, Independent Director | ||
| Gerd Kochendoerfer, Senior Vice President Technical Development & Quality | ||
| William McKee, Independent Director | ||
| James Fogarty, Independent Director | ||
| Srinivas Rao, Chief Medical Officer and Senior Vice President |
Depomed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Depomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.6 | |||
| Return On Asset | -0.31 | |||
| Profit Margin | (0.97) % | |||
| Operating Margin | 14.34 % | |||
| Current Valuation | 1.14 B | |||
| Shares Outstanding | 63.59 M | |||
| Shares Owned By Insiders | 0.61 % | |||
| Shares Owned By Institutions | 98.37 % | |||
| Number Of Shares Shorted | 9.3 M | |||
| Price To Earning | (2.67) X |
Pair Trading with Depomed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Depomed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Depomed will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ATT could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATT when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATT - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ATT Inc to buy it.
The correlation of ATT is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATT moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ATT Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ATT can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Depomed Stock
If you are still planning to invest in Depomed check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Depomed's history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |